Escitalopram Purification via pH-Optimized Liquid-Liquid Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying escitalopram and citalopram are inefficient and costly, particularly on an industrial scale, as they require extensive and time-consuming purification procedures like HPLC to remove impurities formed during synthesis, which are difficult to separate from the desired product.
Innovation Solution
A process involving the dissolution of the pharmaceutically acceptable salt in water, adjusting the pH to 7.0-7.7, extracting with a non-miscible organic solvent, and repeating the extraction steps to isolate and purify escitalopram, effectively removing diamine impurities without relying on expensive HPLC techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If HPLC purification procedures are used to remove impurities from escitalopram, then manufacturing precision is improved, but productivity deteriorates due to extensive and time-consuming procedures
Solution Approach 1:
The invention changes the pH parameter of the aqueous phase to a specific range (pH 7.0-7.7) to optimize the distribution of escitalopram between the aqueous and organic phases. This parameter optimization enables effective purification through simple extraction while avoiding time-consuming HPLC procedures, thus resolving the contradiction between purity and purification speed
Solution Approach 2:
The invention introduces an organic solvent as an intermediary substance to facilitate the separation of escitalopram from impurities. The organic solvent acts as a mediator that selectively extracts escitalopram from the aqueous phase at optimized pH, providing a rapid alternative to HPLC while maintaining high purity levels
2Manufacturing precision
If recrystallization procedures are used to purify escitalopram, then manufacturing precision is improved, but productivity deteriorates due to time-consuming crystallization steps
Solution Approach 1:
The invention extracts impurities from the escitalopram-containing aqueous phase using an organic solvent at specifically optimized pH conditions. This extraction approach directly removes impurities without requiring time-consuming crystallization steps, thereby maintaining high purity while significantly improving purification speed
Solution Approach 2:
The invention optimizes the pH parameter to 7.0-7.7, which is specifically designed to maximize the distribution coefficient of escitalopram between phases while minimizing impurity co-extraction. This parameter optimization enables rapid purification without crystallization, resolving the contradiction between purity and speed
3Manufacturing precision
If multiple extraction steps are performed to remove diamine impurities, then manufacturing precision is improved, but loss of time increases
Solution Approach 1:
The invention optimizes the pH parameter to a narrow range (7.0-7.7) that maximizes the selective extraction of escitalopram while leaving diamine impurities in the aqueous phase. This single optimized extraction step achieves effective impurity removal without requiring multiple sequential extractions, thus reducing purification time while maintaining high precision
Solution Approach 2:
The invention uses a single extraction step with an optimized organic solvent system that achieves sufficient purification in one operation rather than requiring multiple partial extractions. This single excessive action provides adequate purification while minimizing time loss
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly reduces the amount of impurities in escitalopram, achieving high purity without the need for time-consuming crystallization or expensive HPLC processes, making it more economical and suitable for industrial-scale production.
Implementation Method 1
extracting said escitalopram with an organic solvent
Data Source
Figure 1
AI summary
The present invention is concerned with a process in connection with the purification of a pharmaceutically acceptable salt of escitalopram or citalopram.